Clinical Trial Update: Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551) [Phase 3]

View source ↗

Summary

Phase 3 trial results for posaconazole in invasive fungal infection were reported by Merck Sharp & Dohme LLC. The study status is completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Fungal Infection

Drugs mentioned

• NOXAFIL (POSACONAZOLE)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Fungal Infection | Phase 3 | Status: COMPLETED | Results posted: 2011-04-29